Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 22.
doi: 10.1097/HEP.0000000000001359. Online ahead of print.

Prediction models for liver decompensation in compensated advanced chronic liver disease: A systematic review

Vincent Haghnejad  1   2   3 , Laura Burke  1   4 , Siham El Ouahabi  5 , Richard Parker  4 , Ian A Rowe  1   4
Affiliations

Prediction models for liver decompensation in compensated advanced chronic liver disease: A systematic review

Vincent Haghnejad et al. Hepatology. .

Abstract

Background and aims: Identifying individuals with compensated advanced chronic liver disease (cACLD) at risk of decompensation allows for personalized therapy. However, predicting decompensation is challenging, and multiple models have been developed. This study systematically appraises the performance and clinical applications of published multivariable models predicting first decompensation in patients with cACLD or compensated cirrhosis.

Approach and results: We searched MEDLINE for liver decompensation prediction models from inception to December 2023. The research was registered with PROSPERO (CRD42023488395). Model risk of bias and applicability were assessed using the Prediction study Risk of Bias Assessment Tool (PROBAST), with results summarized via narrative synthesis. Reporting followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis and Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies guidelines. Sixteen studies (retrospective and prospective) were included. Seven focused on a single etiology. No study specifically predicted outcomes in persons with alcohol-associated liver disease. Outcome definitions varied, with some models predicting HCC together with decompensation. In total, 27 predictors were included in the models. The most frequent predictors were albumin, platelets, age, liver stiffness, bilirubin, international normalized ratio, and the presence of portal hypertension-related findings during upper gastrointestinal endoscopy. All studies reported discrimination measures, but only 10/16 evaluated calibration. External validation was conducted in 9/16 studies. Thirteen studies were rated as having a high overall risk of bias.

Conclusions: For clinical utility, a predictive model must accurately describe future risks. Models for predicting decompensation in cACLD are often poorly described, infrequently include patients with ArLD, and lack external validation. These factors are barriers to the clinical utility and uptake of predictive models for first decompensation in patients with cACLD.

Keywords: cACLD; compensated cirrhosis; liver cirrhosis; multivariable prediction models; predictive.

PubMed Disclaimer

References

    1. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76:959–974.
    1. Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J Hepatol. 2022;77:1014–1025.
    1. Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification. National Institute for Health and Care Excellence (NICE); 2023. Accessed April 30, 2024. http://www.ncbi.nlm.nih.gov/books/NBK554923/
    1. Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): A randomised, double-blind, placebo-controlled, multicentre trial. Lancet Lond Engl. 2019;393:1597–1608.
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. The BMJ. 2009;339:b2700.

LinkOut - more resources